The Wall Street Journal's "Pharmalot" reporter Ed Silverman reports on a bill introduced in the California legislature that is aimed at elucidating the mysteries of prescription drug pricing: As the prices of prescription medicines strain budgets, one California lawmaker wants to force drug makers to reveal their costs in a bid to provide some transparency […]
Category Archives: Uncategorized
From the Bangor Daily News: A federal judge has overturned Maine’s first-in-the-nation law allowing residents to purchase medication by mail from other countries. U.S. Chief District Judge Nancy Torresen’s ruling Monday comes more than a year after several Maine pharmacy groups filed suit against the state over the 2013 law, arguing it jeopardizes the safety […]
As many of our readers know, as required by the Dodd-Frank financial reform legislation, the Consumer Financial Protection Bureau is conducting a study of arbitration as a dispute-resolution mechanism for matters with the Bureau's regulatory reach. After the study, the CFPB is authorized to take regulatory action consistent with its study's results. (We addressed the […]
From the New York Times: After two years of imposing increasingly stiff penalties on automakers that overstate their fuel economy ratings, federal regulators on Monday said they would tighten guidelines used in determining the mileage advertised to consumers. Next year, automakers will face stricter rules for conducting a crucial test or face an audit by […]
We've discussed before the fight between federal regulators and airbag manufacturer Takata over whether the company would issue a nationwide recall on defective airbags. The confrontation is escalating. As the New York Times reported Friday: federal regulators said on Friday that they would begin to fine the Japanese auto supplier $14,000 a day, saying it […]
Consumer Financial Protection Bureau Chairman Richard Cordray spoke yesterday at a meeting of the National Association of Attorneys General. His remarks are posted here. Chairman Cordray discussed CFPB's efforts to address deceptive marketing, debt traps, "dead ends" (a discussion of credit scores and debt collection), and discrimination.
Though the definition varies (go here), a patent troll generally is thought of as a person or entity that buys patents and then enforces the patents through litigation against accused infringers to collect licensing fees. The troll has no intent to exploit the patent for itself — that is, no plan to use the patent […]
Law professors Anthony Casey and Eric Posner attempt to answer that question in A Framework for Bailout Regulation. Here is the abstract: During the height of the financial crisis in 2008 and 2009, the government bailed out numerous corporations, including banks, investment banks, and automobile manufacturers. While the bailouts helped end the financial crisis, they […]
by Paul Alan Levy The Appellate Division in New York has today affirmed the denial of a pre-litigation petition brought by Woodbridge Structured Funding seeking to compel Opinion Corp. to provide identifying information about the authors of two critical consumer reviews on its Pissed Consumer site.
The latest Obamacare challenge, now pending before the Supreme Court, could if successful cost the states a lot of money. How much? Read the Post's analysis, complete with a state-by-state breakdown and a discussion of its possible implications for the outcome of the case, here.